The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives

Michael A. Vavuranakis, Steven R. Jones, Rhanderson Cardoso, Gary Gerstenblith, Thorsten M. Leucker

Research output: Contribution to journalReview articlepeer-review


High lipoprotein(a) [Lp(a)] levels are associated with the development of atherosclerotic cardiovascular disease (ASCVD) and with calcific aortic valve stenosis (CAVS) both observationally and causally from human genetic studies. The mechanisms are not well characterized but likely involve its role as a carrier of oxidized phospholipids (OxPLs), which are known to be increased in pro-inflammatory states, to induce pro-inflammatory changes in monocytes leading to plaque instability, and to impair vascular endothelial cell function, a driver of acute and recurrent ischemic events. In addition, Lp(a) itself has prothrombotic activity. Current lipid-lowering strategies do not sufficiently lower Lp(a) serum levels. Lp(a)-specific-lowering drugs, targeting apolipoprotein(a) synthesis, lower Lp(a) by up to 90% and are being evaluated in ongoing clinical outcome trials. This review summarizes the current knowledge on the associations of Lp(a) with ASCVD and CAVS, the current role of Lp(a) assessment in the clinical setting, and emerging Lp(a)-specific-lowering therapies.

Original languageEnglish (US)
JournalHellenic Journal of Cardiology
StateAccepted/In press - 2020


  • Cardiovascular disease
  • Lipoprotein(a)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives'. Together they form a unique fingerprint.

Cite this